Home LiteratureArticle Details
PMID: 7841052 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer.

British journal of cancer ·Vol. 71 ·No. 2 ·1995-02-00 ·Pages 354-6

Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S

Abstract

High levels of IL-6 were found in 50% of 114 patients with primary ovarian cancer. IL-6 sensitivity was lower than that of CA 125, and the combination of both assays did not increase the sensitivity of CA 125 alone. However, elevated IL-6 serum levels were correlated with a poor prognosis since patients with low IL-6 levels had a better survival than patients with high IL-6 levels (P = 0.0009). Multivariate analysis revealed that IL-6 positivity has an independent value.

MeSH Terms
Adult Aged Ascites Biomarkers, Tumor/blood CA-125 Antigen/blood Female Humans Interleukin-6/blood Life Tables Middle Aged Multivariate Analysis Neoplasm Proteins/blood Neoplasm Staging Ovarian Neoplasms/blood,mortality,pathology Prognosis Sensitivity and Specificity Survival Analysis
Chemicals
Biomarkers, Tumor CA-125 Antigen Interleukin-6 Neoplasm Proteins
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Scambia G
Department of Gynecology and Obstetrics, Catholic University, Rome, Italy.
Testa U
Benedetti Panici P
Foti E
Martucci R
Gadducci A
Perillo A
Facchini V
Peschle C
Mancuso S
References (16)
16 references, click to expand
  1. Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-up.
    Int J Gynecol Cancer. 1993 Jan;3(1):44-53 PMID: 11578321
  2. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
    Cancer Res. 1992 Jun 15;52(12):3317-22 PMID: 1596890
  3. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha.
    Am J Obstet Gynecol. 1992 Mar;166(3):997-1007 PMID: 1550178
  4. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection.
    J Immunol. 1992 Apr 1;148(7):2175-80 PMID: 1545125
  5. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells.
    J Exp Med. 1989 Nov 1;170(5):1649-69 PMID: 2553849
  6. Human glioblastoma cells release interleukin 6 in vivo and in vitro.
    Cancer Res. 1990 Oct 15;50(20):6683-8 PMID: 2208133
  7. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis.
    Proc Natl Acad Sci U S A. 1990 Apr;87(8):3092-6 PMID: 1691500
  8. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer.
    Am J Obstet Gynecol. 1991 Apr;164(4):1038-42; discussion 1042-3 PMID: 2014824
  9. Interleukin-6 serum levels in patients with gynecological tumors.
    Int J Cancer. 1994 May 1;57(3):318-23 PMID: 8168990
  10. Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.
    Br J Cancer. 1990 Jul;62(1):147-51 PMID: 2167724
  11. Evaluation of survival data and two new rank order statistics arising in its consideration.
    Cancer Chemother Rep. 1966 Mar;50(3):163-70 PMID: 5910392
  12. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.
    J Clin Invest. 1991 Jul;88(1):239-47 PMID: 1647416
  13. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.
    J Immunol. 1988 Sep 1;141(5):1543-9 PMID: 3261754
  14. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas.
    FEBS Lett. 1989 Jul 3;250(2):607-10 PMID: 2787758
  15. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures.
    Cancer Res. 1990 Nov 1;50(21):6959-65 PMID: 2208162
  16. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides.
    Gynecol Oncol. 1993 Apr;49(1):8-15 PMID: 8482564
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/bjc.1995.71
Published
1995-02-00
Pages
354-6
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2033591
Subset
IM
External Links
PubMed source DOI: 10.1038/bjc.1995.71 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2